Abstract
Introduction of immune checkpoint inhibitors (ICI) revolutionized the treatment of relapsed/refractory classical Hodgkin lymphoma (r/r cHL). However, continuous ICI treatment in responding patients (pts) poses a risk of immune-related toxicity and introduces a significant financial burden, raising the question of optimal therapy duration. There is an unmet need for the novel biomarkers to optimize the ICI treatment strategy. We characterized the concentrations of serum soluble programmed death-ligand 1 (sPD-L1), interleukin-6 (IL-6) and interleukin-15 (IL-15) during nivolumab (nivo) therapy and their association with clinical factors, treatment safety and survival.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
